Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT02715258

Public ClinicalTrials.gov record NCT02715258. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).

Study identification

NCT ID
NCT02715258
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Theracos
Industry
Enrollment
210 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2016
Primary completion
Mar 31, 2017
Completion
Mar 31, 2017
Last update posted
Jun 27, 2021

2016 – 2017

United States locations

U.S. sites
18
U.S. states
8
U.S. cities
18
Facility City State ZIP Site status
Research Site Canoga Park California 91303
Research Site Chino California 91710
Research Site Huntington Park California 90255
Research Site Los Angeles California 90057
Research Site San Diego California 92103
Research Site Fort Lauderdale Florida 33316
Research Site Hialeah Florida 33012
Research Site Miami Lakes Florida 33016
Research Site Orlando Florida 32806
Research Site Port Orange Florida 32127
Research Site Trenton New Jersey 08611
Research Site Calabash North Carolina 28467
Research Site Morehead City North Carolina 28557
Research Site Munroe Falls Ohio 44262
Research Site Portland Oregon 97239
Research Site North Myrtle Beach South Carolina 29582
Research Site DeSoto Texas 75115
Research Site Fort Worth Texas 76164

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02715258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02715258 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →